1887

Abstract

Lysostaphin is a glycylglycine endopeptidase. It cleaves the pentaglycine cross-bridge structure unique to the staphylococcal cell wall and is considered to be a potential drug for . In the present study, the activity of recombinant lysostaphin was investigated in 257 isolates collected from hospital patients in Beijing, China, by determination of MIC and minimum bactericidal concentration (MBC) and a time–kill curve test. An agar dilution method was used for MIC determination in all of the isolates and a macrobroth dilution method was employed to verify MIC values for a subset of the isolates. All of the strains were sensitive to the recombinant lysostaphin with MICs ranging from 0.03 to 2 μg ml in the agar dilution assay. The antibacterial activity of lysostaphin was greater than that of vancomycin and other reference agents. For most of the isolates, the MICs from the agar dilution method were higher than those from the broth dilution method. The MBCs of lysostaphin in the test isolates were between 1- and 8-fold higher than their MIC values. Bactericidal activity (>99.9 % reduction) was observed after 2 h exposure of the isolates to lysostaphin at concentrations of ⩾0.5 MIC. Lysostaphin showed a rapid bactericidal activity against the test strains of meticillin-susceptible and meticillin-resistant . Its activity at ⩾0.5 MIC was sustained for at least 6 h. These results will be informative for the clinical application and evaluation of lysostaphin.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46788-0
2007-01-01
2019-11-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/56/1/71.html?itemId=/content/journal/jmm/10.1099/jmm.0.46788-0&mimeType=html&fmt=ahah

References

  1. Aires de Sousa, M., Crisóstomo, M. I., Sanches, I. S., Wu, J. S., Fuzhong, J., Tomasz, A. & de Lencastre, H. ( 2003; ). Frequent recovery of a single clonal type of multidrug-resistant Staphylococcus aureus from patients in two hospitals in Taiwan and China. J Clin Microbiol 41, 159–163.[CrossRef]
    [Google Scholar]
  2. Berger-Bächi, B. & Rohrer, S. ( 2002; ). Factors influencing methicillin resistance in staphylococci. Arch Microbiol 178, 165–171.[CrossRef]
    [Google Scholar]
  3. Climo, M. W., Patron, R. L., Goldstein, B. P. & Archer, G. L. ( 1998; ). Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob Agents Chemother 42, 1355–1360.
    [Google Scholar]
  4. Climo, M. W., Ehlert, K. & Archer, G. L. ( 2001; ). Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 45, 1431–1437.[CrossRef]
    [Google Scholar]
  5. Dajcs, J. J., Thibodeaux, B. A., Hume, E. B. H., Zheng, X., Sloop, G. D. & O'Callahan, R. J. ( 2001; ). Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit. Curr Eye Res 22, 451–457.[CrossRef]
    [Google Scholar]
  6. Goldberg, L. M., DeFranco, J. M., Watanakunakorn, C. & Hamburger, M. ( 1967; ). Studies in experimental staphylococcal endocarditis in dogs. VI. Treatment with lysostaphin. Antimicrob Agents Chemother 7, 45–53.
    [Google Scholar]
  7. Harrison, E. F. & Zygmunt, W. A. ( 1967; ). Lysostaphin in experimental renal infections. J Bacteriol 93, 520–524.
    [Google Scholar]
  8. Kiri, N., Archer, G. & Climo, M. W. ( 2002; ). Combinations of lysostaphin with β-lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis. Antimicrob Agents Chemother 46, 2017–2020.[CrossRef]
    [Google Scholar]
  9. Kokai-Kun, J. F., Walsh, S. M., Chanturiya, T. & Mond, J. J. ( 2003; ). Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother 47, 1589–1597.[CrossRef]
    [Google Scholar]
  10. Kusuma, C. M. & Kokai-Kun, J. F. ( 2005; ). Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus. Antimicrob Agents Chemother 49, 3256–3263.[CrossRef]
    [Google Scholar]
  11. McCoy, M. ( 2004; ). Killing staph together: start-up Biosynexus places fermentation project in newly started Avecia facility. Chem Eng News 82, 36–40.
    [Google Scholar]
  12. Mierau, I., Leij, P., van Swam, I., Blommestein, B., Floris, E., Mond, J. & Smid, E. J. ( 2005; ). Industrial-scale production and purification of a heterologous protein in Lactococcus lactis using the nisin-controlled gene expression system NICE: the case of lysostaphin. Microb Cell Fact 4, 15.[CrossRef]
    [Google Scholar]
  13. National Committee for Clinical Laboratory Standards ( 1999; ). Methods for Determining Bactericidal Activity of Antimicrobial Agents, approved guideline M26-A. Wayne, PA: National Committee for Clinical Laboratory Standards.
  14. National Committee for Clinical Laboratory Standards ( 2003a; ). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, approved standard M7-A6. Wayne, PA: National Committee for Clinical Laboratory Standards.
  15. National Committee for Clinical Laboratory Standards ( 2003b; ). MIC Testing: Supplemental Tables, supplement M100-S13 (M7). Wayne, PA: National Committee for Clinical Laboratory Standards.
  16. Patron, R. L., Climo, M. W., Goldstein, B. P. & Archer, G. L. ( 1999; ). Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 43, 1754–1755.
    [Google Scholar]
  17. Polak, J., Latta, P. D. & Blackburn, P. ( 1993; ). In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 17, 265–270.[CrossRef]
    [Google Scholar]
  18. Schindler, C. A. & Schuhardt, V. Y. ( 1964; ). Lysostaphin: a new bacteriolytic agent for the staphylococcus. Proc Natl Acad Sci U S A 51, 414–421.[CrossRef]
    [Google Scholar]
  19. Srinivasan, A., Dick, J. D. & Perl, T. M. ( 2002; ). Vancomycin resistance in Staphylococci. Clin Microbiol Rev 15, 430–438.[CrossRef]
    [Google Scholar]
  20. von Eiff, C., Kokasi-Kun, J. F., Becker, K. & Peters, G. ( 2003; ). In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from anterior nares and blood. Antimicrob Agents Chemother 47, 3613–3615.[CrossRef]
    [Google Scholar]
  21. Wu, B., Tang, Y., Zhang, K., Zhang, T., Zhu, J. & Tan, S. ( 2002; ). Staphylococcus heterogeneously resistant to vancomycin in China and antimicrobial activities of imipenem and vancomycin in combination against it. J Clin Microbiol 40, 1109–1112.[CrossRef]
    [Google Scholar]
  22. Wu, J. A., Kusuma, C., Mond, J. J. & Kokai-Kun, J. F. ( 2003; ). Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob Agents Chemother 47, 3407–3414.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.46788-0
Loading
/content/journal/jmm/10.1099/jmm.0.46788-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error